PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,314 shares of the business’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $77.93, for a total transaction of $180,330.02. Following the transaction, the vice president owned 111,312 shares in the company, valued at approximately $8,674,544.16. The trade was a 2.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mark Elliott Boulding also recently made the following trade(s):

• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total transaction of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total value of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.99, for a total value of $213,683.88.

PTC Therapeutics Trading Up 0.1%

Shares of PTCT traded up $0.06 during mid-day trading on Monday, reaching $77.59. The company’s stock had a trading volume of 2,631,928 shares, compared to its average volume of 1,795,906. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The business has a 50-day simple moving average of $76.61 and a two-hundred day simple moving average of $62.91. The stock has a market cap of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. During the same period in the previous year, the firm earned ($1.39) EPS. The firm’s revenue was up 7.2% compared to the same quarter last year. Research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

Analyst Ratings Changes

A number of brokerages recently commented on PTCT. Jefferies Financial Group upped their price target on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Citigroup upped their target price on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $82.00 to $91.00 in a research note on Monday, December 1st. Barclays lifted their price target on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Finally, TD Cowen upped their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $77.27.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC raised its stake in PTC Therapeutics by 587.5% in the fourth quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock valued at $67,943,000 after purchasing an additional 764,364 shares in the last quarter. Diversified Trust Co. increased its holdings in PTC Therapeutics by 4.9% in the 4th quarter. Diversified Trust Co. now owns 17,394 shares of the biopharmaceutical company’s stock valued at $1,321,000 after buying an additional 817 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in PTC Therapeutics by 9.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,145 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 806 shares during the period. GAMMA Investing LLC raised its position in shares of PTC Therapeutics by 160.0% in the 4th quarter. GAMMA Investing LLC now owns 1,451 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 893 shares in the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 310 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.